Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2017 | Comparing continuous and fixed duration myeloma treatment with triplets and doublets

Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, speaks about a debate comparing continuous and fixed duration myeloma treatment with triplets and doublets at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He argues that for the majority of myeloma patients, continuous treatment is the best option to date. Dr Terpos speaks about the treatment sequence for transplant-eligible and transplant-ineligible patients, and highlights the efficacy of triplet therapies in relapsed and refractory myeloma. However, he points out that in patients who cannot tolerate triplet therapies, doublets are a good option. He concludes that triplets are more efficacious than doublets, but that doublets may be very efficacious for specific subsets of patients. In addition, he concludes that continuous treatment seems to give the best results for both transplant-eligible and transplant-ineligible patients.